See more : Yunnan Baiyao Group Co.,Ltd (000538.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Trevena, Inc. (TRVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trevena, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sarissa Capital Acquisition Corp. (SRSAW) Income Statement Analysis – Financial Results
- Allfunds Group plc (ALLFG.AS) Income Statement Analysis – Financial Results
- Zhejiang Tederic Machinery Co., Ltd. (603289.SS) Income Statement Analysis – Financial Results
- Standard Industries Limited (SIL.BO) Income Statement Analysis – Financial Results
- First Rate Staffing Corporation (FRSI) Income Statement Analysis – Financial Results
Trevena, Inc. (TRVN)
About Trevena, Inc.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.13M | -418.00K | 567.00K | 3.07M | 31.00K | 5.73M | 0.00 | 3.75M | 6.25M | 0.00 | 134.98K | 807.60K | 2.42M |
| Cost of Revenue | 1.67M | 3.02M | 954.00K | 182.00K | 108.00K | 0.00 | 490.00K | 0.00 | 44.07M | 40.55M | 18.76M | 13.29M | 0.00 |
| Gross Profit | 1.46M | -3.44M | -387.00K | 2.89M | -77.00K | 5.73M | -490.00K | 3.75M | -37.82M | -40.55M | -18.63M | -12.49M | 2.42M |
| Gross Profit Ratio | 46.56% | 822.01% | -68.25% | 94.07% | -248.39% | 100.00% | 0.00% | 100.00% | -605.18% | 0.00% | -13,800.00% | -1,546.24% | 100.00% |
| Research & Development | 16.33M | 18.21M | 13.43M | 13.12M | 13.29M | 15.82M | 48.97M | 89.96M | 44.07M | 40.55M | 18.76M | 13.29M | 15.11M |
| General & Administrative | 0.00 | 0.00 | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.41M | 34.73M | 38.11M | 19.25M | 13.21M | 18.98M | 19.64M | 16.08M | 12.80M | 9.40M | 4.72M | 3.12M | 3.06M |
| Other Expenses | 0.00 | 2.71M | 337.00K | 416.00K | 2.25M | 459.00K | 614.00K | -711.00K | 92.93K | 184.02K | 1.25K | 122.79K | 0.00 |
| Operating Expenses | 38.41M | 52.94M | 51.54M | 32.37M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Cost & Expenses | 38.41M | 55.96M | 52.49M | 32.55M | 26.50M | 34.80M | 68.61M | 106.03M | 56.87M | 49.95M | 23.48M | 16.42M | 18.17M |
| Interest Income | 2.25M | 451.00K | 162.00K | 240.00K | 418.00K | 1.00M | 679.00K | 743.00K | 331.21K | 17.37K | 884.00 | 754.00 | 3.54K |
| Interest Expense | 0.00 | 1.26M | 1.00K | 29.00K | 931.00K | 2.23M | 2.78M | 1.74M | 334.37K | 70.65K | 149.76K | 193.74K | 74.22K |
| Depreciation & Amortization | 893.00K | 864.00K | 841.00K | 830.00K | 863.00K | 645.00K | 490.00K | 246.00K | 207.90K | 239.39K | 706.78K | 787.52K | 801.58K |
| EBITDA | -35.29M | -55.51M | -51.08M | -28.66M | -25.61M | -28.43M | -68.12M | -101.01M | -50.62M | -49.71M | -22.64M | -14.65M | -14.95M |
| EBITDA Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -74,961.29% | -482.27% | 0.00% | -2,727.55% | -809.94% | 0.00% | -16,770.17% | -1,820.09% | -617.21% |
| Operating Income | -35.29M | -56.38M | -51.93M | -29.49M | -26.58M | -30.50M | -70.39M | -102.28M | -50.62M | -49.95M | -23.35M | -15.61M | -15.75M |
| Operating Income Ratio | -1,129.22% | 13,486.84% | -9,157.85% | -960.74% | -85,741.94% | -532.07% | 0.00% | -2,727.55% | -809.94% | 0.00% | -17,295.37% | -1,932.90% | -650.46% |
| Total Other Income/Expenses | -4.68M | 2.71M | 337.00K | 416.00K | 1.71M | 459.00K | -3.25M | -711.00K | 92.76K | 249.13K | 93.85K | -25.62K | -59.79K |
| Income Before Tax | -39.97M | -53.67M | -51.59M | -29.07M | -24.87M | -30.04M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Income Before Tax Ratio | -1,279.07% | 12,839.71% | -9,098.41% | -947.18% | -80,229.03% | -524.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| Income Tax Expense | 318.00K | -2.71K | -428.00K | 300.00K | 3.19M | 745.00K | 3.39M | -246.00K | -207.90K | 254.67K | 151.00K | 316.53K | 74.22K |
| Net Income | -40.29M | -53.67M | -51.16M | -29.37M | -28.06M | -30.78M | -71.87M | -102.99M | -50.53M | -49.70M | -23.25M | -15.64M | -15.81M |
| Net Income Ratio | -1,289.25% | 12,839.07% | -9,022.93% | -956.96% | -90,503.23% | -537.06% | 0.00% | -2,746.51% | -808.45% | 0.00% | -17,225.84% | -1,936.08% | -652.93% |
| EPS | -54.51 | -14.88 | -7.82 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| EPS Diluted | -54.51 | -14.88 | -7.77 | -4.86 | -7.65 | -10.46 | -30.23 | -49.14 | -28.84 | -50.40 | -22.59 | -28.41 | -38.03 |
| Weighted Avg Shares Out | 739.05K | 3.61M | 6.54M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
| Weighted Avg Shares Out (Dil) | 739.05K | 3.61M | 6.58M | 6.05M | 3.67M | 2.94M | 2.38M | 2.10M | 1.75M | 986.22K | 1.03M | 550.43K | 415.72K |
Trevena (TRVN) to Begin Clinical Study on Pain Candidate
Trevena (TRVN) advances TRV045 into clinical development as a potential treatment for diabetic neuropathic pain. Enrollment in the study is expected to begin in the first quarter of 2022.
Trevena Offers An Enticing Risk-Reward At These Prices
Trevena continues to struggle to get OLINVYK off the launch pad. COVID-19 headwinds are persisting, and it is having an impact on the company's ability to get through P&T committees. Trevena is building a body of evidence in OLINVYK's post-approval...
Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers
Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates
Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q3 2021 Results - Earnings Call Transcript
Trevena, Inc. (TRVN) CEO Carrie Bourdow on Q3 2021 Results - Earnings Call Transcript
Trevena Reports Third Quarter 2021 Results
-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets
Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
Patricia Drake appointed new Chief Commercial Officer Patricia Drake appointed new Chief Commercial Officer
Trevena to Release Third Quarter 2021 Financial Results on November 15th, 2021
Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET Company to host conference call on Monday, November 15th, 2021 at 8:00 a.m. ET
Trevena Announces Two OLINVYK® Presentations at ANESTHESIOLOGY® 2021
Posters highlight safety and tolerability data in two complex patient populations at higher risk for adverse events Posters highlight safety and tolerability data in two complex patient populations at higher risk for adverse events
5 Penny Stocks To Watch This Week With Potential Biotech Catalysts
Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports